Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid
Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2264-2286
DOI: 10.1021/acs.jmedchem.3c01892 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.02.2024. Verfasst von Anjali Negi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Nitroimidazoles, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Science and Engineering Research Board, University Grants Committee.
Abstract (Originalsprache)
Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis (anti-TB) treatment regimens and have emerged as potential solutions for combating drug-resistant TB. These drugs have proven to be effective in treating drug-resistant TB when used in combination. However, concerns have been raised about the eventual loss of these drugs due to evolving resistance mechanisms and certain adverse effects such as prolonged QT period, gastrointestinal problems, hepatotoxicity, and renal disorders. This Perspective emphasizes the properties of these first-in-class drugs, including their mechanism of action, pharmacokinetics/pharmacodynamics profiles, clinical studies, adverse events, and underlying resistance mechanisms. A brief coverage of efforts toward the generation of best-in-class leads in each class is also provided. The ongoing clinical trials of new combinations of these drugs are discussed, thus providing a better insight into the use of these drugs while designing an effective treatment regimen for resistant TB cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
- Natural Products and Medicinal Chemistry, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India.
ORCID-Profile: Rashmi Sharma
Förderung
- Council of Scientific and Industrial Research, India
- Science and Engineering Research Board
- University Grants Committee
Zitieren
APA
Negi, A., Perveen, S., Gupta, R., Singh, P. P., & Sharma, R. (2024). Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid. Journal of Medicinal Chemistry, 67(4), 2264-2286. https://doi.org/10.1021/acs.jmedchem.3c01892
Vancouver
Negi A, Perveen S, Gupta R, Singh PP, Sharma R. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid. Journal of Medicinal Chemistry. 2024;67(4):2264-2286. doi:10.1021/acs.jmedchem.3c01892
BibTeX
@article{Negi2024,
author = {Negi, Anjali and Perveen, Summaya and Gupta, Ria and Singh, Parvinder Pal and Sharma, Rashmi},
title = {Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {4},
pages = {2264--2286},
doi = {10.1021/acs.jmedchem.3c01892}
}
EUVIMED